Develops cell therapies for autoimmune diseases.
Dec 2025Revenue $0.00/yrExpenses $122M/yr
No trendCash runway ≈ 1.9 years from Jun 2026
Figures by year
When will Nkarta be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $122M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $122M | −$122M |
| Dec 2024 | $0.00 | $128M | −$128M |
| Dec 2019 | $115K | $22.5M | −$22.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.